

Source details

Gaceta Medica de Caracas

Scopus coverage years: from 1954 to 1957, from 1959 to 1965, from 1971 to 1976, from 1978 to 1988, from 2008 to 2014, from 2017 to Present

Publisher: Academia Nacional de Medicina

ISSN: 0367-4762

Subject area: Medicine: General Medicine

Source type: Journal

CiteScore 2022

0.2



SJR 2022

0.117



SNIP 2022

0.152



[View all documents >](#)

[Set document alert](#)

[Save to source list](#) [Source Homepage](#)

[CiteScore](#) [CiteScore rank & trend](#) [Scopus content coverage](#)

Improved CiteScore methodology



CiteScore 2022 counts the citations received in 2019-2022 to articles, reviews, conference papers, book chapters and data papers published in 2019-2022, and divides this by the number of publications published in 2019-2022. [Learn more >](#)

CiteScore 2022

$$0.2 = \frac{121 \text{ Citations 2019 - 2022}}{507 \text{ Documents 2019 - 2022}}$$

Calculated on 05 May, 2023

CiteScoreTracker 2023

$$0.3 = \frac{171 \text{ Citations to date}}{586 \text{ Documents to date}}$$

Last updated on 05 September, 2023 • Updated monthly

CiteScore rank 2022

Category	Rank	Percentile
Medicine		
General Medicine	#749/830	9th

[View CiteScore methodology >](#) [CiteScore FAQ >](#) [Add CiteScore to your site](#)



Publish Open Access
Regional Studies
 Make an impact.
 tandfonline.com

Gaceta Medica de Caracas

COUNTRY	SUBJECT AREA AND CATEGORY	PUBLISHER	H-INDEX
Venezuela 	Medicine Medicine (miscellaneous)	Academia Nacional de Medicina	5

PUBLICATION TYPE	ISSN	COVERAGE	INFORMATION
Journals	03674762	1954-1957, 1959-1965, 1971-1976, 1978-1988, 2008-2014, 2017-2020	Homepage

SCOPE

Gaceta Médica de Caracas Órgano de la Academia Nacional de Medicina y del Congreso Venezolano de Ciencias Médicas Salud Fundada el 13 de marzo de 1893 Trimestral GMC

Join the conversation about this journal




Nursing Research and Practice

Japan-made wire cut EDM

Our reliable wire cutting EDM machine is known for its high accuracy easy operation.

Seibu Electric&Machinery



Japan-made wire cut EDM

Our reliable wire cutting EDM machine is known for its high accuracy easy operation.

Seibu Electric&Machinery



FIND SIMILAR JOURNALS

Expat Born After 1948?

24/7 Support + 1st Tier Hospital + Global Expe

Top Expat Insurance

1
F1000Research

2
Science Translational

3
Current Opinion in

4
Journal of Intern

Nursing Research and Practice


similarity

similarity


similarity

similarity


SJR




Total Documents




Total Cites Self-Cites



Citations per document




External Cites per Doc Cites per Doc




- Cites / Doc. (4 years)
- Cites / Doc. (3 years)
- Cites / Doc. (2 years)


% International Collaboration



Citable documents Non-citable documents



Cited documents Uncited documents



Gaceta Medica de Caracas

← Show this widget in your own website

Q4 Medicine (miscellaneous) best quartile

Just copy the code below and paste within your html

Nursing Research and Practice

Depósito legal DC2020001347 ISSN 2739-0012

GACETA MEDICA


DE CARACAS

Fundada el 13 de marzo de 1893

por el

DR. LUIS RAZETTI

Organo de la Academia Nacional de Medicina
y del Congreso Venezolano de Ciencias Médicas



VOLUMEN 129 - N° 3

Julio - Septiembre 2021

Caracas - Venezuela

Indizada en

AMELYCA, AURA, BASE, BASE DE DATOS PERIODICA, BIBLAT,
BIREME, CABELLS SCHOLARLY ANALYTICS, CROSS REF, DIRECTORY
OF OPEN ACCESS JOURNAL(DOAJ), Elsevier Scopus, EuroPub, GOOGLE
ANALYTICS, GOOGLE SCHOLAR, Latindex, LILACS, MIAR, ORCID,
PUBLONS, PubMed, REDEB, Research Gate, REPOSITORIO SABER UCV,
SCIELO, SCIMAGO, WEB OF SCIENCE, WORLDCAT

Comité Editorial de la Gaceta Médica de Caracas (Editorial Board)

Editor en jefe (Editor in Chief)

Dr. Manuel Velasco (UCV, ACADEMIA NACIONAL DE MEDICINA, Venezuela)

Editor consultante (Consulting Editor)

Dr. Enrique Santiago López Loyo (ACADEMIA NACIONAL DE MEDICINA, Venezuela)

Editor Gerente (Senior Editor)

Dra. Anita Stern de Israel (UCV, Venezuela)

Editores Honorarios (Honorary Editors in Chief)

Dr. Antonio Clemente (ACADEMIA NACIONAL DE MEDICINA, Venezuela)

Dr. Rafael Muci Mendoza (ACADEMIA NACIONAL DE MEDICINA, Venezuela)

Dra. Doris Perdomo de Ponce (ACADEMIA NACIONAL DE MEDICINA, México)

Editores Asociados (Associate Editors)

Dr. Harry Acquatella (ACADEMIA NACIONAL DE MEDICINA, Venezuela)

Dra. Lissé Chiquinquirá Angarita Dávila (Universidad Andres Bello: Talcahuano, Concepción, Biobio, CL Chile)

Dr. Claudio Aoün (ACADEMIA NACIONAL DE MEDICINA, Venezuela)

Dr. Gustavo Aroca (Universidad Simón Bolívar, Colombia)

Dr. Alexis Bello (Hospital de Clínicas, Caracas, Venezuela)

Dr. Leopoldo Briceño-Iragorry (ACADEMIA NACIONAL DE MEDICINA, Venezuela)

Dra. Lilia Cruz (ACADEMIA NACIONAL DE MEDICINA, Venezuela)

Dr. Jorge Escobedo (UNIVERSIDAD AUTÓNOMA DE MÉXICO, México)

Dr. Mariano Fernández (UCV, Venezuela)

Dr. José Francisco (ACADEMIA NACIONAL DE MEDICINA, Venezuela)

Dr. José María Guevara (ACADEMIA NACIONAL DE MEDICINA, Venezuela)

Dr. Saúl Kízer (ACADEMIA NACIONAL DE MEDICINA, Venezuela)

Dr. Saúl Krivoy (ACADEMIA NACIONAL DE MEDICINA, EE. UU)

Dr. Felipe Martín Piñate (ACADEMIA NACIONAL DE MEDICINA, Venezuela)

Dr. José Parra (Universidad de Guadalajara, México)

Dra. Diana Marcela Rojas (Universidad Andrés Bello: Talcahuano, Concepción, Biobio, CL, Chile)

Dr. Tomas Sanabria (ACADEMIA NACIONAL DE MEDICINA, Venezuela)

Dra. Enriqueta Sileo (ACADEMIA NACIONAL DE MEDICINA, Venezuela)

Dr. Marco Sorgi (ACADEMIA NACIONAL DE MEDICINA, Venezuela)

Dr. Andrés Soyano (ACADEMIA NACIONAL DE MEDICINA, Venezuela)

Dr. Huniades Urbina (ACADEMIA NACIONAL DE MEDICINA, Venezuela)

Dra. Ofelia Uzcátegui (ACADEMIA NACIONAL DE MEDICINA, Venezuela)

Dr. Horacio Vanegas (ACADEMIA NACIONAL DE MEDICINA, Venezuela)

Dr. Juan Yabur (ACADEMIA NACIONAL DE MEDICINA, Venezuela)

Editores Ejecutivos (Executive Guest Editors)

Dr. Luis Alcocer (Universidad Autónoma de México, México)
Dr. Ezequiel Bellorin Font (Universidad de Cleveland, EE. UU)
Dr. Raúl Carlini (Hospital Universitario, Caracas, Venezuela)
Dr. Guillermo Colmenares (ACADEMIA NACIONAL DE MEDICINA, Venezuela)
Dr. Manuel Guzmán Blanco (Centro Médico de Caracas, Venezuela)
Dr. Zafar Israili (Universidad de Emory, EE. UU)
Dra. Isis Nézer de Landaeta (ACADEMIA NACIONAL DE MEDICINA, Venezuela)
Dra. Alicia Ponte Sucre (IME-UCV, Venezuela)
Dr. Heberto Suarez Roca (LUZ, EE. UU)
Dr. Herbert Stegeman (ACADEMIA NACIONAL DE MEDICINA, Venezuela)

Editores de Sección (Section Editors)

Dr. Oscar Aldrey (Instituto Médico, La Floresta, Venezuela)
Dr. Valmore Bermúdez (USB, Colombia)
Dra. Claudia Blandenier de Suárez (ACADEMIA NACIONAL DE MEDICINA, Venezuela)
Dr. Claudio Borghi (Universidad de Bologna, Italia)
Dr. Juan De Sanctis (Universidad de Olomouc, República Checa)
Dr. Luis Juncos (**J Robert Cade Foundation**, Argentina)
Dr. Carlos Ferrario (Universidad de Carolina del Norte, EE. UU)
Dr. Claudio Ferri (**Università degli Studi dell'Aquila**, Italia)
Dr. Patricio López Jaramillo (**Universidad Autónoma de Bucaramanga (UNAB)**, Colombia)
Dr. Héctor Marcano (Hospital Universitario de Caracas, Venezuela)
Dr. Oscar Noya (Instituto de Medicina Tropical, UCV, Venezuela)
Dr. José Andrés Octavio (Hospital de Clínicas Caracas, Venezuela)
Dr. José A O'Daly (ACADEMIA NACIONAL DE MEDICINA, Venezuela)
Dr. Stefano Omboni (Italian Institute of Telemedicine, Italia)
Dr. Gianfranco Parati (University of Milano-Bicocca, Italia)
Dr. José Ramón Poleo (ACADEMIA NACIONAL DE MEDICINA, Venezuela)
Dr. Bernardo Rodríguez Iturbe (Instituto Nacional Ignacio Chávez, México)
Dr. Félix Tapia (Instituto de Biomedicina-UCV, Venezuela)

Editores Asistentes (Assistant Editors)

Dr. Henry Collet Camarillo (Clínica Ávila, Venezuela)
Dr. Freddy Contreras (UCV, Venezuela)
Dr. Giuseppe Crippa (Unidad de Hipertensión Arterial Piacenza, Italia)
Dra. Maricarmen Chacín (USB, Colombia)
Dra. María Sofía Martínez Cruz (Universidad de Virginia, EE. UU)
Dra. Dolores Moreno (Instituto de Biología Molecular -UCV, Venezuela)
Dr. Alexis García (Instituto de Inmunología, UCV, Venezuela)
Dra. Jenny Garmendia (Instituto de Biología Molecular-UCV, Venezuela)
Dr. Edward Rojas (Universidad de Virginia, EE. UU)
Dr. Juan Salazar (La Universidad del Zulia, Venezuela)
Dr. Francisco Tortoledo (España)

Gaceta Médica de Caracas

PALABRAS
CLAVE

[Analgesia Brain](#)

[COVID-19](#)

[Cáncer Hipertensión](#)

[José Gregorio](#)

[Hernández](#)

[Laparoscopia](#)

[Meningioma Mente](#)

[Mind Mortalidad Niños](#)

[Nocebo Placebo](#)

[Prevención SARS-](#)

[CoV-2 Tuberculosis](#)

[Venezuela](#)

[Venezuela. embarazo
pandemic](#)

INICIO	ACERCA DE...	INGRESAR
REGISTRO	BUSCAR	ACTUAL
ARCHIVOS	ANUNCIOS	NORMATIVA PARA
AUTORES	COMITÉ EDITORIAL	TWITTER

Inicio > Archivos > **Vol 129, No 2S (2021)**

Vol 129, No 2S (2021)

Tabla de contenidos

NÚMERO COMPLETO

Acceso a la Revista completa GMC [PDF](#)
129(Suplemento 2)2021
Gaceta Médica

ÍNDICE

Ver el contenido del presente número en español [PDF](#)

INDEX

Ver el contenido del presente número en inglés [PDF](#)

ACADÉMICOS

Junta Directiva, Individuos de Número, Miembros Correspondientes Nacionales y Extranjeros, Invitados de Cortesía y Comisiones de la ANM [PDF](#)
Gaceta Médica V-VI

COMISIONES CIENTÍFICAS

Comisiones Científicas para el bienio 2020-2022 [PDF](#)
Gaceta Médica IX-XI

NORMAS

Revise las Normas para los autores de publicaciones en la Gaceta Médica de Caracas [PDF](#)
XII-XIV

EDITORIAL

[Multidisciplinary Research in Medicine Science during COVID-19 Pandemic](#) [PDF](#)
Muhammad Miftahussurur S273-S276

[OPEN JOURNAL SYSTEMS](#)

[Ayuda de la revista](#)

USUARIO/A

Usuario/a

Contraseña

Recordar mis datos

NOTIFICACIONES

- [Ver](#)
- [Suscribirse / Des-suscribirse](#)

INFORMACIÓN

- [Para lectoras/es](#)
- [Para autoras/es](#)
- [Para bibliotecarias/os](#)

CONTENIDO

Buscar

 Todos

Navegar

- [Por número](#)
- [Por autor](#)
- [Por título](#)
- [Otras revistas](#)

TAMAÑO DE FUENTE

ARTÍCULOS ORIGINALES

<u>Serum HDL-c and LDL-c levels as the predictors of COVID-19 severity</u>	PDF
<i>Andro P. Witarto, Achmad JE. Putra, Shidi L. Pramudito</i>	S277-S292
<u>Correlation of HbA1c levels and diabetic neuropathy complications in diabetes mellitus patients</u>	
<i>Anisatul Hamida, Laily Irfana, Detty Nur Irawati</i>	S293-S298
<u>The proper use of face mask during COVID-19 pandemic in urban community</u>	PDF
<i>Jongky Hendro Prajitno, Sulistiawati Kahexa Firman, Jefferson Caessario, Nihal Sofyan, Bagus Ari, Anak Agung Putri, Alfi Nureta, Aulia Rafikasari, Liofelita Christi, Hamzah Farouq</i>	S299-S304
<u>Soluble CD163 and small dense LDL cholesterol levels in type 2 diabetes patients</u>	PDF
<i>Hermina Novida, Soebagijo Adi Soelistijo, Ari Sutjahjo</i>	S305-S312
<u>Analysis of eosinophil and lymphocyte concentrations on the incidence of mild and severe acute asthma exacerbations.</u>	PDF
<i>Raihan Syarif Humaidy, Mohammad Subkhan, Nurma Yuliyanasari, Nabil Salim Ambar</i>	S313-S318
<u>The effect of smoking degree on the incidents of cataracts.</u>	PDF
<i>Nyimas Salsabila Rahma, Yudith Annisa Ayu Rezkitha, Kaniraras Lintang Prameswari, Kartika Prahasanti</i>	S319-S323
<u>Immunoglobulin-E and Thyroid-Stimulating Hormone Receptor Antibody in Graves' disease with Atopy.</u>	PDF
<i>Rio Wironegoro, Ari Baskoro, Chairul Effendi, Agung Pranoto</i>	S324-S327
<u>Maternal age and parity associated with low birth weight infants</u>	PDF
<i>Intan Afifah, Ninuk Dwi Ariningtyas, Gina Noor Djalilah, Muhammad Anas</i>	S328-S333
<u>Etiological pathogen causes of diarrhea in children</u>	PDF
<i>Esa Widhanar, Musa Ghufron, Nenny Triastuti, Edim Hartati</i>	S334-S339
<u>A descriptive analysis of the spatiotemporal distribution of hepatitis A virus outbreak in Pacitan, East Java, Indonesia</u>	PDF
<i>Aditya Doni Pradana, Raissa Virgy Rianda, Zhanna Ovitha Riskhathusa, Swastika A. S. Asri, Rama Azalix Rianda, Aris Istianah, Ratha-korn Vilaichone, Muhammad Miftahussurur</i>	S340-S349
<u>Characteristics of patients with dengue hemorrhagic fever and its relationship with the prevalence of dengue shock syndrome in children</u>	PDF
<i>Edim Hartati, Muhammad Anas, Gina Noor Djalilah, Ayu Lidya Paramita</i>	S350-S356
<u>Effects of treadmill exercises on pancreatic β cell function through the role of vitamin D in patients with type 2 diabetes mellitus.</u>	PDF
<i>Anugrahini Irawati, Sony Wibisono Mudjanarko, Damayanti Tinduh</i>	S357-S366
<u>Malondialdehyde levels and clinical</u>	PDF

<u>outcomes assessed by the modified Rankin scale in patients with acute intracerebral hemorrhagic stroke</u>	
<i>Abdulloh Machin, Nurlisa Naila Aulia, Sita Setyowatie</i>	S367-S372
<u>Association between bleeding volume with heme oxygenase-1 and malondialdehyde levels in patients of acute intracerebral hemorrhage.</u>	PDF
<i>Sita Setyowatie, Abdulloh Machin, Nurlisa Naila Aulia</i>	S373-S378
<u>Triple elimination in pregnant women in Indonesia</u>	PDF
<i>Dinda Sella Octaviana, Afif Nurul Hidayati, Muhammad Ilham Aldika Akbar, Muhammad Miftahussurur</i>	S379-S389
<u>COVID-19 and hepatitis B Ambassador of Surabaya, Indonesia: Motivation, commitment, and knowledge of youth generation towards health programs in the pandemic era.</u>	PDF
<i>Ricky Indra Alfaray, Firyal Nadiyah Rahmah, Lionardy Yodianto, Abu Rizal Dwikatmono Johan, Muhammad Raihan Habibi, Shod Abdurrachman, Yudith Annisa Ayu Rezkitha, Reny I'tishom, Yoshio Yamaoka, Muhammad Miftahussurur</i>	S390-S402
<u>Relationship on the performance of doctors in inpatients towards the level of patient satisfaction.</u>	PDF
<i>Ilham Daud Samodra, Tjatur Prijambodo, Musa Ghufron, Sri Widyaningsih</i>	S403-S408
<u>Differences in the characteristics of long-term contraceptive device acceptors compared to short-term ones</u>	PDF
<i>M. Frando Ghiffari Ekwanda, Uning Marlina, Nova Primadina</i>	S409-S415
<u>Factors associated with the success of exclusive breastfeeding in the rural area</u>	PDF
<i>Reza Putri Maghriza, Ninuk Dwi Ariningtyas, Yelvi Levani, Musa Ghufron</i>	S416-S422
<u>Admission assessment criteria in predicting students' academic performance in newly established medical school</u>	PDF
<i>Nurma Yuliyanasari, Laily Irfana, Kartika Prahasanti, Syafarinah Nur Hidayah Akil</i>	S423-S428
<u>The effect of Ramadan fasting on clinical and laboratory parameters in chronic kidney disease patients underwent hemodialysis</u>	PDF
<i>Langgeng Perdhana, Shofa Chasani</i>	S429-S435
<u>Effect of astaxanthin on malondialdehyde level in damaged cerebral cortex tissue in male rat (<i>Rattus norvegicus</i>) induced by formaldehyde orally.</u>	PDF
<i>Erik Ahmad Hasyim, Virhan Novianry, Mistika Zakiah, Andriani ., Dyan Roshinta Laksmi Dewi</i>	S436-S441
<u>Intradialytic and post-dialytic complications in chronic kidney disease patients undergoing maintenance hemodialysis</u>	PDF
<i>Alvin Henri, Christine Christine, Mario Gregorius Barbarigo Nara</i>	S442-S447
<u>Pulmonary tuberculosis patients with diabetes mellitus have a more severe</u>	PDF

<u>degree of chest X-ray compared to pulmonary tuberculosis patients without diabetes mellitus</u>	
<i>Muhammad Ramzi, Muslim Andala Putra, Mohammad Subkhan</i>	S448-S453
	PDF
<u>The importance of health-related to quality-of-life assessment in pulmonary tuberculosis patients: A literature review.</u>	
<i>Angga Dimas Mahendra, Yudith Annisa Ayu Rezkitha, Nur Mujaddidah Mochtar, Afrita Amalia Laitupa</i>	S454-S462
	PDF
<u>Correlation of pre-operating antibiotic types with surgical site infection in post-appendectomy patients</u>	
<i>Fitria Romadoni, Handayani ., Aditya Bhayusakti</i>	S463-S468
	PDF
<u>Respiratory allergy with concentration ability in young adults</u>	
<i>Handayani ., Evi Sylvia Awwalia</i>	S469-S475
	PDF
<u>Mental health, depression, and quality of life levels in heart failure patients.</u>	
<i>Abraham Ahmad Ali Firdaus, Nur Azizah, Silvia .</i>	S476-S483
	PDF
<u>Profile of unnatural mortality at tertiary hospital.</u>	
<i>Mustika Chasanatusy Syarifah, Diyan Wahyu Kurniasari</i>	S484-S488
	PDF
<u>Characteristics of reproductive-aged women with unmet need for family planning</u>	
<i>Nadia Rochmaya, Uning Marlina, Nova Primadina</i>	S489-S494
	PDF
<u>Karo Traditional Oil, a traditional herbal medicine from Indonesia promote wound healing acceleration by suppressing tumor necrosis factor – α and stimulating interleukin 10 production</u>	
<i>Nova Primadina</i>	S495-S502



Este trabajo está licenciado bajo la licencia [Creative Commons Attribution 3.0](#).

ISSN: 2739-0012

Soluble CD163 and small dense LDL cholesterol levels in type 2 diabetes patients

CD163 soluble y niveles de colesterol LDL denso pequeño en pacientes con diabetes tipo 2

Hermina Novida^{1*}, Soebagijo Adi Soelistijo^{2*}, Ari Sutjahjo^{3*}

SUMMARY

Introduction: The sdLDL cholesterol proportion is a better marker for the prediction of cardiovascular diseases (CVDs). Macrophages play a crucial role in both initiation and progression of atherosclerosis, the underlying mechanism of CVDs. This study investigated the correlation between soluble CD163 as a biomarker macrophage activation and sdLDL cholesterol in type 2 diabetes mellitus (T2DM) subjects for the first time.

Methods: This study was an observational analytic

cross-sectional study involved 40 patients with T2DM in Surabaya, Indonesia. The sdLDL was measured using a direct enzymatic colorimetric method using Architect c8000. The levels of sCD163 were measured by a quantitative enzyme immunoassay technique using a specific monoclonal antibody for human CD163 using Quantikine® Elisa produced by R&D Systems Inc., USA.

Results: The average level of HbA1c in this study was 8.01 ± 1.39 %, and more than half of the subjects had HbA1c levels >8 % that revealed most of the patients in this study were in poor glycemic control. The average sdLDL cholesterol level in this study was 40.80 ± 19.14 mg/dL, and the mean of soluble CD163 was 741.22 ± 41.55 ng/mL. There were no differences in gender (male or female), glycemic control (<8 % vs >8 %), hypertension, and smoking on sCD163 levels and sdLDL cholesterol levels. We found a positive correlation between the soluble CD163 level with sdLDL ($r=0.440$, $p=0.004$).

Conclusion: The atherogenic lipoprotein fraction sdLDL cholesterol level correlated with soluble CD163 level. This could be a new link between lipid dysregulation, innate immunity, and atherosclerosis in T2DM.

Keywords: sdLDL, soluble CD163, atherosclerosis, T2DM.

DOI: <https://doi.org/10.47307/GMC.2021.129.s2.5>

ORCID: 0000-0001-5899-1589¹

ORCID: 0000-0002-7594-0123²

ORCID: 0000-0003-3304-7406³

^{*}Division of Endocrinology, Metabolism, and Diabetes, Department of Internal Medicine Faculty of Medicine Universitas Airlangga-Dr. Soetomo General Hospital, Surabaya, Indonesia

• Corresponding Author: Hermina Novida, MD, PhD
Division of Endocrinology, Metabolism, and Diabetes, Department of Internal Medicine Faculty of Medicine Universitas Airlangga-Dr. Soetomo General Hospital, Surabaya, Indonesia

Tel: +6231-502-3865; Fax: +6231-502-3865

E-mail: hermina-n@fk.unair.ac.id

Recibido: 5 de mayo 2021

Aceptado: 22 de junio 2021

RESUMEN

Introducción: La proporción de sdLDL colesterol es un mejor marcador para la predicción de enfermedades cardiovasculares (ECV). Los macrófagos juegan un

papel crucial tanto en el inicio como en la progresión de la aterosclerosis, el mecanismo subyacente de las ECV. Este estudio investigó la correlación entre CD163 soluble como un biomarcador de activación de macrófagos y colesterol sdLDL en sujetos con diabetes mellitus tipo 2 (T2DM) por primera vez.

Métodos: Este estudio fue un estudio transversal analítico observacional que involucró a 40 pacientes con DM2 en Surabaya, Indonesia. La sdLDL se midió mediante un método colorimétrico enzimático directo usando Architect c8000. Los niveles de sCD163 se midieron mediante una técnica de inmunoensayo enzimático cuantitativo usando un anticuerpo monoclonal específico para CD163 humano usando Quantikine® Elisa producido por R&D Systems Inc., EE.UU.

Resultados: El nivel promedio de HbA1c en este estudio fue $8,01 \pm 1,39$ %, y más de la mitad de los sujetos tenían niveles de HbA1c > 8 % que revelaron que la mayoría de los pacientes en este estudio tenían un control glucémico deficiente. El nivel medio de colesterol sdLDL en este estudio fue $40,80 \pm 19,14$ mg/dL y la media de CD163 soluble fue $741,22 \pm 41,55$ ng/mL. No hubo diferencias en sexo (hombre o mujer), control glucémico (<8 % vs >8 %), hipertensión y tabaquismo en los niveles de sCD163 y los niveles de sdLDL colesterol. Se encontró una correlación positiva entre el nivel de CD163 soluble con sdLDL ($r = 0,440$, $p = 0,004$).

Conclusión: El nivel de sdLDL colesterol de la fracción de lipoproteínas aterogénicas se correlacionó con el nivel de CD163 soluble. Este podría ser un nuevo vínculo entre la desregulación de lípidos, la inmunidad innata y la aterosclerosis en la DM2.

Palabras clave: sdLDL, CD163 soluble, aterosclerosis, DM2.

INTRODUCTION

Type 2 diabetes mellitus (T2DM) is related to an increase in the risk of coronary heart disease incidence, ischemic stroke, and mortality. T2DM also affects life quality by increasing the risk of heart failure, peripheral artery insufficiency, and microvascular complications. It is also affected life expectancy by decreasing about 4–8 years in patients with diabetes, compared to individuals without diabetes (1). The mechanisms of the pathogenesis of cardiovascular diseases (CVDs) in T2DM are associated with epigenetic, genetic, and cell-signaling defects in inter-related metabolic and inflammatory

pathways (2). The association of T2DM and CVDs is affected by environmental factors and phenotypes of the patients. Patients with T2DM are often accompanied by other conditions such as dyslipidemia, hypertension, inflammation, procoagulant state, or thrombosis, representing risk factors for CVDs (3).

T2DM involves abnormalities in carbohydrate and lipid metabolism. Dyslipidemia is one of the comorbidities often present in patients with T2DM, which may stimulate and facilitate atherogenesis and the atherosclerosis process. Proteins help the distribution of lipids as their properties allow them to remain in the circulatory system. Those proteins are categorized according to their molecular density into very-low-density lipoprotein (VLDL), low-density lipoprotein (LDL), and high-density lipoprotein (HDL). Along with triglycerides, lipid clusters lipoproteins circulate along vessels to distal organs and tissues (3,4). LDL cholesterol plays a crucial role in the development and progression of atherosclerosis and CVD, especially in T2DM (5).

LDL consists of several subclasses with different sizes and densities of particles, including large buoyant LDL (IbLDL), intermediate LDL, and small dense LDL (sdLDL) (6). It has been well established that sdLDL has a greater atherogenic potential than other LDL sub-fractions. The proportion of sdLDL is a better predictor of cardiovascular disease than total LDL-C. The circulation time of sdLDL is longer than that of large LDL particles that are cleared from the bloodstream through the interaction with the LDL receptor. Circulating sdLDL has a lower affinity to LDL receptors, and multiple atherogenic modifications in blood plasma, such as desialylation, glycation, and oxidation, increase its atherogenicity (5,7,8). Circulating sdLDL cholesterol levels are also associated with systemic inflammation (9). Dyslipidemia and systemic inflammation, which is the leading hypothesis to explain the pathogenesis of atherosclerosis, are related to sdLDL cholesterol (10,11).

Immune system activation is associated with T2DM progression. Hyperglycemia induces an apoptotic mechanism producing inflammation in pancreatic beta cells. IL-6 stimulates apoptosis in pancreatic islets together with other inflammatory

cytokines and acts as a predictor for the progression of T2DM. Oxidative stress may also potentiate the generation of free radical oxygen and proinflammatory cytokines that disrupts and destroys the beta cells. Adaptive and innate immunity responses are involved in adipose tissue inflammation in T2DM. The phenotype switching of macrophages from predominantly anti-inflammatory M2-type to increased proportions of proinflammatory M1-type macrophages plays a critical role in the stimulation and progression of islet inflammation. The recruitment of B cells and T cells precedes adipose tissue infiltration by macrophages (12-14).

CD163 is a receptor for haptoglobin-hemoglobin complexes and is expressed solely on macrophages and monocytes. The extracellular portion of CD163 circulates in the blood as a soluble protein (sCD163) and increases acutely due to metalloproteinase-mediated cleavage near the cell membrane during inflammation and macrophage activation. The sCD163 is very useful as a biomarker of macrophage activation in various inflammatory diseases. Macrophage infiltration of adipose tissue and the liver is strongly related to the progression of T2DM (15,16). The sCD163 was associated with myocardial infarction and coronary artery disease in the population cohort (17), carotid intima-media thickness in older people (18). The sCD163 also accelerates atherosclerosis in systemic lupus erythematosus (19) and increases vulnerable plaque in human immunodeficiency virus (HIV) patients (20).

Therefore, we conduct this study to find the relationship between the sCD163 as a marker of macrophage activation and sdLDL as a predictor of CVDs risk in patients with T2DM from a tertiary referral hospital in Surabaya, Indonesia.

MATERIAL AND METHOD

Design and Population Study

This study was a cross-sectional analytic observational study that involved 40 participants with T2DM from the diabetes outpatient clinic in Dr. Soetomo general hospital, Surabaya, Indonesia. Subjects with T2DM with age more

than 40 years old were recruited in the study. All subjects were on statin therapy as a part of diabetes management. Diagnosis of T2DM based on medical record or fulfilled Indonesian Society of Endocrinology Criteria 2015 (21). Subjects with acute complications of diabetes (such as ketoacidosis, sepsis, and acute infection), renal and liver impairment, chronic hepatitis, liver cirrhosis, pregnancy, HIV infection, steroid therapy, and autoimmune disease were excluded from the study. All participants gave their informed consent to participate in the study approved by the local Ethics Committee.

Data Collection

Interview and vital signs were performed in all subjects. A digital sphygmomanometer measured blood pressure (BP) after allowing the patients to rest for 15 minutes before the examination. Hypertension was defined by JNC VIII criteria (22), which subjects with systolic blood pressure ≥ 140 mmHg and diastolic blood pressure ≥ 90 mmHg. Weight and height were measured in all subjects, and body mass index (BMI) was calculated. The smoking status was assessed by recording the habit and duration of smoking, which active smoker was defined as the subject had >100 cigarettes during life. Blood samples were collected after an overnight fast to measure sCD163 and sdLDL cholesterol levels, biochemical variables such as triglycerides, total cholesterol, HDL, LDL cholesterol. Fasting plasma glucose, 2 hours postprandial glucose, and HbA1c levels were also measured using standard techniques. The sdLDL was measured using a direct enzymatic colorimetric method using Architect c8000. The levels of sCD163 were measured by a quantitative enzyme immunoassay technique using a specific monoclonal antibody for human CD163 using Quantikine® Elisa produced by R&D Systems Inc., USA.

Statistical Analysis

Statistical analyses were performed using SPSS for Windows, version 13.0 (SPSS Inc., Chicago, IL, USA). Continuous variables were expressed as the mean \pm standard deviation. Categorical variables were expressed as group

percentages. The mean of the group was analyzed using Student t-test analysis. The distribution of data was analyzed using the Kolmogorov-Smirnov test. Pearson's correlation was utilized to demonstrate the correlations between sCD163 and sdLDL levels if the data distribution was normal.

RESULTS

Clinical characteristic of the subjects

General characteristics of subjects such as age,

sex, height, weight, BMI, and clinical features of T2DM, hypertension, and lipid profile were described in Table 1. There were 17 male and 23 female subjects. The average BMI was 25.66 ± 2.91 , and the duration of diabetes was 8.13 ± 5.77 years. The average level of fasting plasma glucose was 150.20 ± 61.97 mg/dL, postprandial plasma glucose was 214.20 ± 33.64 mg/dL, and HbA1c was 8.13 ± 5.77 mg/dL. There were no different characteristics between male and female subjects in this study.

Table 1
Clinical characteristics of subjects

Characteristics	Mean ± SD		
	All (n=40)	Male (n=17)	Female (n=23)
Age (years old)	59.55 ± 8.14	60.82 ± 7.85	59.55 ± 8.14
Height (cm)	156.93 ± 7.35	162.88 ± 5.85	156.93 ± 7.35
Weight (kg)	63.20 ± 8.06	63.91 ± 8.39	63.20 ± 8.06
Body Mass Index (BMI)(kg/m ²)	25.66 ± 2.91	24.04 ± 2.37	26.86 ± 2.72
Type 2 Diabetes Mellitus			
- Duration (years)	8.13 ± 5.77	8.52 ± 5.99	7.83 ± 5.73
- Fasting plasma glucose (mg/dL)	150.20 ± 61.97	151.82 ± 67.44	149.00 ± 59.13
- Postprandial plasma glucose (mg/dL)	214.20 ± 33.64	227.29 ± 83.44	204.52 ± 67.39
- HbA1c (%)	8.01 ± 1.39	8.00 ± 1.50	8.02 ± 1.33
Hypertension			
- Systolic blood pressure (mmHg)	144.20 ± 20.15	145.58 ± 6.00	143.17 ± 3.43
- Diastolic blood pressure (mmHg)	87.57 ± 10.72	86.30 ± 1.88	89.29 ± 3.09
Lipid Profile			
- Total cholesterol (mg/dL)	213.20 ± 33.64	214.23 ± 24.58	212.43 ± 39.56
- LDL cholesterol (mg/dL)	145.02 ± 33.92	148.41 ± 30.21	142.52 ± 36.89
- HDL cholesterol (mg/dL)	45.25 ± 11.98	42.47 ± 7.20	47.30 ± 14.36
- Triglyceride (mg/dL)	172.07 ± 51.38	170.47 ± 44.43	173.26 ± 56.93

Soluble CD163 levels

The average levels of sCD163 in this study were 741.22 ± 41.55 ng/mL. There were no differences of gender (male or female), glycemic control (< 8 % versus > 8 %), hypertension, and smoking on sCD163 levels were found in this study (Table 2).

Small dense LDL cholesterol levels

The average levels of sdLDL cholesterol in this study were 40.80 ± 19.14 mg/dL. The sCD163 levels in this study were not affected by gender (male or female), glycemic control (<8 % versus >8 %), hypertension, and smoking (Table 3).

Table 2
Soluble CD163 level in all subjects

Variable	n (%)	Mean ± SD (ng/mL)	p
All subjects	40 (100)	741.22 ± 41.55	
Gender			
- Male	17 (42.50)	729.97 ± 64.51	0.559
- Female	23 (57.50)	749.53 ± 55.25	
Glycemic control			
- <8 %	19 (47.50)	732.64 ± 259.22	0.784
- >8 %	21 (52.50)	748.97 ± 271.03	
Hypertension			
- Yes	30 (75.00)	728.48 ± 260.56	0.522
- No	10 (25.00)	779.42 ± 277.47	
Smoking			
- Yes	7 (12.50)	634.92 ± 261.03	0.817
- No	33 (87.50)	763.76 ± 260.80	

Table 3
Small dense LDL level in all subjects

Variable	n (%)	Mean ± SD (mg/dL)	p
All subjects	40 (100)	40.80 ± 19.14	
Sex			
- Male	17 (42.50)	40.87 ± 14.59	0.132
- Female	23 (57.50)	40.75 ± 22.24	
Glycemic control			
- <8 %	19 (47.50)	42.63 ± 20.74	0.412
- >8 %	21 (52.50)	39.14 ± 17.92	
Hypertension			
- Yes	30 (75.00)	39.23 ± 17.97	0.437
- No	10 (25.00)	45.52 ± 22.67	
Smoking			
- Yes	7 (12.50)	48.88 ± 22.57	0.592
- No	33 (87.50)	39.08 ± 18.27	

Correlation between soluble CD163 and sdLDL

The distribution of data was analyzed using the Kolmogorov-Smirnov test. The data distribution in this study was normal, then the correlation between sCD163 and sd LDL cholesterol levels was continued to analyze using the Pearson correlation test. There was a significant correlation between sCD163 and sd LDL cholesterol levels with p 0.004 and a correlation coefficient of 0.440 (Figure 1).




Figure 1. The correlation plot between sCD163 and sdLDL in all subjects.

DISCUSSION

We found there was a positive correlation between soluble CD163 and sdLDL in T2DM patients. The CD163 is a member of the scavenger receptor superfamily, categorized into class B, and its soluble form is a marker of activated M2 macrophages. Increased plasma levels of sdLDL were one of the predictors of atherosclerosis and cardiovascular disease in many previous studies. A positive correlation between soluble CD163 and sdLDL showed there is a link between innate immunity and the atherogenic process in the T2DM population.

Our study was also the first study that measured the soluble CD163 in the diabetes population in Indonesia. The mean of soluble CD163 levels was 741.22 ng/mL (similar to 0.741 mg/L). Although we did not have soluble CD163 data in a healthy population in Indonesia, another study in Scandinavia found that soluble CD163 levels were 0.7–3.9 mg/L in healthy individuals (16). Gender, glycemic control, hypertension, and smoking did not affect soluble CD163 levels in this study. The average level of HbA1c was 8.01 ± 1.39 %, above the target of HbA1c for T2DM. More than half of the subjects had HbA1c levels > 8 % that revealed most subjects in this study were in poor glycemic control. It was similar to the Diabcare Asia study that showed the mean levels of HbA1c in Indonesia was 8.3 ± 2.2 %, and 48.5 % of patients had HbA1c levels > 8 % (23).

Another study in subjects with type 1 diabetes mellitus, that gender did not associate with soluble CD163 levels (24), but it is different from a study in Arab Saudi, which is showed that systolic and diastolic blood pressure had an association with soluble CD163 (25). Smoking also did not give a different effect to soluble CD163 in the HIV population (26), similar to this study.

In this study, we assessed the relationship between soluble CD163 as a marker of macrophage inflammation with sdLDL as a predictor of CVD risk in the T2DM population in a tertiary referral hospital in Indonesia. This study used sdLDL cholesterol level instead of LDL cholesterol, because many individuals with LDL levels within the normal range, still develop atherosclerosis and cardiovascular disease. This

implies a significant heterogeneity of LDL-particles, as the sub-fraction of small dense LDL exhibits enhanced atherogenic potential. Small dense LDL has a stronger predisposition for oxidation, lower LDL-receptor affinity, and an increased accumulation within the vascular wall (27,28). Several studies have established an association of elevated sdLDL levels with atherosclerosis and cardiovascular disease (5,7-9). The other study showed that high levels of plasma sdLDL were associated with an increased risk of major cardiovascular events among T2DM patients with coronary artery disease (29).

Monocytes and macrophages have been involved in all stages of atherogenesis, from initiation and progression to destabilization and rupture of atherosclerotic lesions. This was shown in stable coronary artery disease patients was shown there was the association of sdLDL serum levels and circulating monocyte subsets. Circulating monocytes used three distinct subtypes according to their surface expression of CD14 and CD16 (28).

During the early stages of atherosclerosis, oxidized low-density lipoproteins accumulated in the intima, stimulate the activation of endothelial cells and vascular smooth muscle cells, inducing expression and secretion of proinflammatory cytokines, and adhesion molecules that attract monocytes within the arterial wall. Monocytes continued to differentiate into the macrophages to remove oxidized LDL. There are two phenotypes of macrophages, the M1-type macrophage has a direct effect on pathogen killing, while the M2-type macrophage expresses high levels of scavenging molecules and anti-inflammatory cytokines (30). M2-type macrophages express high levels of CD163, a member of the scavenger receptor cysteine-rich family (30). The soluble form of CD163 is a normal constituent in plasma and is generated by proteolytic cleavage of CD163 at the cell surface. This receptor is now known as an immunomodulatory of atherosclerotic plaque, with anti-inflammatory and anti-atherogenic function. The soluble CD163 levels are increased in patients with atherosclerosis (28).

There were several limitations of this study that have to be considered. First, this is a single-center study from a tertiary referral hospital with a small number of patients. Second, the cross-sectional

study design only allows us to find associations between soluble CD163 and sdLDL, but could not define the causal relationship. Third, we did not differentiate subjects with CVD and non-CVD in this study. However, this study indicates a link between innate immunity and lipid metabolism in atherosclerosis-related diseases, such as T2DM.

CONCLUSION

This study gives evidence for the first time for a positive correlation between soluble CD163 as a marker of macrophage activation and atherogenic sdLDL-cholesterol levels. This result might represent a new link between an atherogenic lipoprotein phenotype and innate immunity in T2DM. Further studies are needed to understand the mechanistic relationship between macrophage activation, small dense LDL, and their specific roles in atherosclerosis-related diseases.

REFERENCES

- Bertoluci MC, Rocha VZ. Cardiovascular risk assessment in patients with diabetes. *Diabetol Metab Syndr*. 2017;9(25).
- Samuel K, Plutzky Jorge, El-Osta Assam. Epigenetic Changes in Diabetes and Cardiovascular Risk. *Circ Res*. 2016;118(11):1706-1722.
- Rodriguez-Araujo G, Nakagami H. Pathophysiology of cardiovascular disease in diabetes mellitus. *Cardiovasc Endocrinol Metab*. 2018;7(1):4-9.
- Ramasamy I. Recent advances in physiological lipoprotein metabolism. *Clin Chem Lab Med*. 2014;52(12):1695-1727.
- Ivanova EA, Myasoedova VA, Melnichenko AA, Grechko A V, Orekhov AN. Small dense low-density lipoprotein as biomarker for atherosclerotic diseases. *Oxid Med Cell Longev*. 2017;2017.
- Zaki Khalil RMA, Al-Azab DAM, Akl OA. Is sdLDL a valuable screening tool for cardiovascular disease in patients with metabolic syndrome? *Alexandria J Med*. 2017;53(4):299-305.
- Duran EK, Aday AW, Cook NR, Buring JE, Ridker PM, Pradhan AD. Triglyceride-rich lipoprotein cholesterol, small dense LDL cholesterol, and incident cardiovascular disease. *J Am Coll Cardiol*. 2020;75(17):2122 LP-2135.
- QiaoZhen X, AiGuo M, Tong W, JingJing L, HaiYing L. Correlation between of small dense low-density lipoprotein cholesterol with acute cerebral infarction and carotid atherosclerotic plaque stability. *J Clin Lab Anal*. 2019;33.
- Fan J, Liu Y, Yin S, Chen N, Bai X, Ke Q, et al. Small dense LDL cholesterol is associated with metabolic syndrome traits independently of obesity and inflammation. *Nutr Metab*. 2019;16(1):1-9.
- Pothineni NVK, Subramany S, Kuriakose K, Shirazi LF, Romeo F, Shah PK, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. *Eur Heart J*. 2017;38(43):2459-2472.
- Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. *Eur Heart J*. 2017;38(32):2459-2472.
- Westwell-Roper CY, Ehses JA, Verchere CB. Resident macrophages mediate islet amyloid polypeptide-induced islet IL-1 β production and β -cell dysfunction. *Diabetes*. 2014;63(5):1698-16711.
- Butcher MJ, Hallinger D, Garcia E, Machida Y, Chakrabarti S, Nadler J, et al. Association of proinflammatory cytokines and islet resident leucocytes with islet dysfunction in type 2 diabetes. *Diabetologia*. 2014;57(3):491-501.
- Tsalamandris S, Antonopoulos AS, Oikonomou E, Papamikroulis G, Vogiatzi G. Risk factors and cardiovascular disease prevention the role of inflammation in diabetes: Current concepts and future perspectives. *Eur Cardiol Rev*. 2019;14(1):50-59.
- Buechler C, Eisinger K, Krautbauer S. Diagnostic and prognostic potential of the macrophage specific receptor CD163 in inflammatory diseases. *Inflamm Allergy Drug Targets*. 2013;12(6):391-402.
- Møller HJ. Soluble CD163. *Scand J Clin Lab Invest*. 2012;72(1):1-13.
- Guo L, Akahori H, Harari E, Smith SL, Polavarapu R, Karmali V, et al. CD163+ macrophages promote angiogenesis and vascular permeability accompanied by inflammation in atherosclerosis. *J Clin Invest*. 2018;128(3):1106-1124.
- Durda Jon. Circulating soluble CD163 and risk of cardiovascular disease and all-cause mortality in older persons: The Cardiovascular Heart Study (CHS). *Circulation*. 2015;131(Suppl 1):AP363-AP363.
- Burdo TH, Lo J, Abbara S, Wei J, DeLelys ME, Preffer F, et al. Soluble CD163, a novel marker of activated macrophages, is elevated and associated

SOLUBLE CD163 AND LDL CHOLESTEROL LEVELS

- with noncalcified coronary plaque in HIV-infected patients. *J Infect Dis.* 2011;204(8):1227-1236.
20. David C, Divard G, Abbas R, Escoubet B, Chezel J, Chauveheid MP, et al. Soluble CD163 is a biomarker for accelerated atherosclerosis in systemic lupus erythematosus patients at apparent low risk for cardiovascular disease. *Scand J Rheumatol.* 2020;49(1):33-37.
 21. Soelistijo SA, Novida H, Rudijanto A, Soewondo P, Suastika K, Manaf A, et al. Konsensus pengelolaan dan pencegahan diabetes melitus tipe 2 di Indonesia 2015. Jakarta PB Perkeni. 2015:1-93.
 22. Armstrong C. JNC8 guidelines for the management of hypertension in adults. *Am Fam Physician.* 2014;90(7):503-504.
 23. Cholil AR, Lindarto D, Pemayun TGD, Wisnu W, Kumala P, Puteri HHS. DiabCare Asia 2012: Diabetes management, control, and complications in patients with type 2 diabetes in Indonesia. *Med J Indones.* 2019;28(1):47-56.
 24. Melin EO, Dereke J, Hillman M. Female sex, high soluble CD163, and low HDL-cholesterol were associated with high galectin-3 binding protein in type 1 diabetes. *Biol Sex Differ.* 2019;10(1):1-9.
 25. Al-Daghri N, Al-Attas O, Bindahman L, Alokail M, Alkharfy K, Draz H, et al. Soluble CD163 is associated with body mass index and blood pressure in hypertensive obese Saudi patients. *Eur J Clin Invest.* 2012;42:1221-1226.
 26. Kooij KW, Wit FWNM, Booiman T, van der Valk M, Schim van der Loeff MF, Kootstra NA, et al. Cigarette smoking and inflammation, monocyte activation, and coagulation in HIV-infected individuals receiving antiretroviral therapy, compared with uninfected individuals. *J Infect Dis.* 2016;214(12):1817-1821.
 27. Summerhill VI, Grechko A V., Yet SF, Sobenin IA, Orekhov AN. The atherogenic role of circulating modified lipids in atherosclerosis. *Int J Mol Sci.* 2019;20(14).
 28. Krychtiuk KA, Kastl SP, Pfaffenberger S, Lenz M, Hofbauer SL, Wannerth A, et al. Association of small dense LDL serum levels and circulating monocyte subsets in stable coronary artery disease. *PLoS One.* 2015;10(4).
 29. Jin JL, Zhang HW, Cao YX, Liu HH, Hua Q, Li YF, et al. Association of small dense low-density lipoprotein with cardiovascular outcome in patients with coronary artery disease and diabetes: A prospective, observational cohort study. *Cardiovasc Diabetol.* 2020;19(1):1-10.
 30. Gutiérrez-Muñoz C, Méndez-Barbero N, Svendsen P, Sastre C, Fernández-Laso V, Quesada P, et al. CD163 deficiency increases foam cell formation and plaque progression in atherosclerotic mice. *FASEB J.* 2020;(August):1-17.